trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['lung', 'start,(-starti),(-starte)', 'nsclc', 'destiny,lung02', 'sclc', 'trastuzumab deruxtecan']
dr. koichi goto starts the lung mini oral session with results from destiny-lung02 of the recently approved trastuzumab deruxtecan in #her2 nsclc #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him